151 related articles for article (PubMed ID: 19265858)
21. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer.
Kohli M; Kaushal V; Spencer HJ; Mehta P
Urology; 2003 Apr; 61(4):765-9. PubMed ID: 12670562
[TBL] [Abstract][Full Text] [Related]
22. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
23. New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostate-specific antigen monitoring.
Fritz BE; Hauke RJ; Stickle DF
Ann Clin Biochem; 2009 May; 46(Pt 3):253-6. PubMed ID: 19264827
[TBL] [Abstract][Full Text] [Related]
24. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
[TBL] [Abstract][Full Text] [Related]
25. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
26. [The PSA caught out].
Gauchez AS; Lamy PJ; Descotes JL
Prog Urol; 2015 Dec; 25(16):1121-4. PubMed ID: 26475234
[TBL] [Abstract][Full Text] [Related]
27. Repeated spurious elevation of serum prostate-specific antigen values solved by chemiluminescence analysis: A possible interference by heterophilic antibodies.
Domínguez A; Bayó M; Muñoz-Rodríguez J; Bellido JA; Abascal-Junquera JM; Hannaoui N; Banús JM
Korean J Urol; 2015 Nov; 56(11):785-7. PubMed ID: 26568798
[TBL] [Abstract][Full Text] [Related]
28. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
29. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy.
Heyns CF
Ann Oncol; 2010 Apr; 21(4):903-904. PubMed ID: 19951953
[No Abstract] [Full Text] [Related]
30. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
31. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
32. [Management of prostate cancer in Senegal: what is being done?].
Niang L; Ndoye M; Ouattara A; Jalloh M; Labou M; Thiam I; Kouka SC; Diaw JJ; Gueye SM
Prog Urol; 2013 Jan; 23(1):36-41. PubMed ID: 23287482
[TBL] [Abstract][Full Text] [Related]
33. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.
Higano CS
J Clin Oncol; 2014 Apr; 32(11):1107-11. PubMed ID: 24590651
[TBL] [Abstract][Full Text] [Related]
34. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.
Kim SO; Kang TW; Kwon D; Park K; Ryu SB
Int Braz J Urol; 2009; 35(2):183-8; discussion 189. PubMed ID: 19409122
[TBL] [Abstract][Full Text] [Related]
36. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
38. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
39. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Fujita M; Goto T; Uchida K; Saiki S; Arima R
Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
[TBL] [Abstract][Full Text] [Related]
40. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer.
Dosoretz AP; Yu JB
J Clin Oncol; 2016 May; 34(15):1718-22. PubMed ID: 27001587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
